Genentech dives deeper into the microbiome, inking $534M deal with Microbiotica to develop IBD meds
Roche’s Genentech unit is doubling down on its study of the microbiome, inking a new deal today worth up to $500 million to develop meds based on studying the gut flora.
The deal is with Cambridge, UK-based startup Microbiotica, a spinout of the Wellcome Sanger Institute. The duo is planning a multi-year partnership to discover, develop, and commercialize medicines for inflammatory bowel disease (IBD).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.